P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

• Philippe Moreau,
• Aurore Perrot,
• Meletios A. Dimopoulos,
• Thomas Martin,
• Thierry Facon,
• Marcelo Eduardo Capra,
• Meral Beksac,
• Nicole Armstrong,
• Franck Dubin,
• Sandrine Macé,
• Marie-Laure Risse,
• Christina Tekle,
• Zandra Klippel,
• Paul Richardson

Affiliations

Philippe Moreau

1 Department of Hematology, University Hospital of Nantes

Aurore Perrot

2 CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie

Meletios A. Dimopoulos

3 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine

Thomas Martin

4 University of California San Francisco Medical Center

Thierry Facon

5 Department of Hematology, Lille University Hospital

Marcelo Eduardo Capra

6 Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus

Meral Beksac

7 Department of Hematology, Ankara University

Nicole Armstrong

8 Sanofi, Global Medical Affairs

Franck Dubin

9 Sanofi, Research and Development

Sandrine Macé

9 Sanofi, Research and Development

Marie-Laure Risse

9 Sanofi, Research and Development

Christina Tekle

10 Sanofi

Zandra Klippel

10 Sanofi

Paul Richardson

11 Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School